Analyst Price Targets — CLPT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 21, 2025 2:15 pm | Frank Takkinen | Lake Street | $30.00 | $15.44 | TheFly | ClearPoint Neuro price target raised to $30 from $17 at Lake Street |
| August 27, 2024 8:45 am | Frank Takkinen | Loop Capital Markets | $15.00 | $12.60 | StreetInsider | Clearpoint Neuro Inc. (CLPT) PT Raised to $15 at Lake Street Capital Markets |
| March 13, 2024 4:35 am | Mathew Blackman | Stifel Nicolaus | $9.00 | $7.17 | StreetInsider | Clearpoint Neuro Inc. (CLPT) PT Raised to $9 at Stifel |
Latest News for CLPT
ClearPoint secures EU MDR certification for ClearPoint Navigation Software 3.0.2, expanding precision-guided surgery access across MRI suites and operating rooms.
ClearPoint Neuro is positioned for robust growth in 2026, driven by IRRAS, the PRISM 1.5T system clearance, and the company's new CRO facility. While the immediate future of uniQure's AMT-130 remains unknown, ClearPoint has a large number of drug delivery partners that continue to generate strong data. CLPT's valuation is modest given the company's solid competitive positioning and the step change in revenue that…
ClearPoint Neuro, Inc. (NASDAQ: CLPT) on Friday said it received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2.
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2. "By achieving CE Mark for the ClearPoint Navigation 3.0.2 software, we are able to…
The Company Achieved 20% Comparable Sales Growth in the Fourth Quarter of 2025 at $10.4 Million SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 12, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced preliminary unaudited revenue growth for its fourth quarter of 2025. These…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CLPT.
U.S. House Trading
No House trades found for CLPT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.